drugset / Trial / NCT00810212

Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion

NCT00810212

Phase 1/2 Withdrawn Mesoblast, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate safety and preliminary efficacy of Neofusetm in subjects with a diagnosis of degenerative disc disease (DDD) in 1 or 2 adjacent vertebral levels between L1 and S1 and undergoing posterolateral lumbar fusion.

Timeline

Start
2008-11
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rexlemestrocel-L Cell therapy 2.5e+07 cells
Subject Rexlemestrocel-L Cell therapy 5e+07 cells
Subject Rexlemestrocel-L Cell therapy 7.5e+07 cells